News | February 11, 2022
OPPI-QCI announce awards to celebrate excellence in manufacturing facility 2021
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
The new facility will provide an important boost to vaccine capacity in Africa
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
Subscribe To Our Newsletter & Stay Updated
